Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label cannabidiol for treatment-resistant anxiety in youth
ACTRN12617000825358Phase 2Completed
- Sponsor
- Orygen
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cannabidiol in anxiety disorder, sponsored by Orygen. Primary endpoint: Anxiety severity. Started May 2018; status: completed.
02
Drugs
cannabidiol
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on ACTRN12617000825358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000825358.